Shares of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) have been given an average rating of “Buy” by the eight ratings firms that are presently covering the firm, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold recommendation, three have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $4.70.
A number of analysts have commented on the stock. Piper Jaffray Companies upgraded shares of Arrowhead Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $5.50 price target for the company in a research note on Monday, November 27th. BidaskClub upgraded shares of Arrowhead Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, December 27th. Cantor Fitzgerald set a $2.00 price target on shares of Arrowhead Pharmaceuticals and gave the company a “hold” rating in a research note on Tuesday, December 12th. Chardan Capital restated a “buy” rating and set a $7.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Monday, February 19th. Finally, ValuEngine upgraded shares of Arrowhead Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday, November 30th.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) traded up $0.07 during trading hours on Wednesday, hitting $7.41. 844,208 shares of the stock traded hands, compared to its average volume of 1,350,000. The company has a market cap of $649.23, a price-to-earnings ratio of -15.77 and a beta of 2.40. The company has a quick ratio of 3.87, a current ratio of 3.87 and a debt-to-equity ratio of 0.03. Arrowhead Pharmaceuticals has a 12 month low of $1.42 and a 12 month high of $7.80.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings data on Tuesday, December 12th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.02). The company had revenue of $8.71 million during the quarter, compared to the consensus estimate of $7.32 million. Arrowhead Pharmaceuticals had a negative net margin of 116.17% and a negative return on equity of 42.52%. equities research analysts anticipate that Arrowhead Pharmaceuticals will post -0.71 EPS for the current fiscal year.
In other Arrowhead Pharmaceuticals news, COO Bruce D. Given sold 20,000 shares of the business’s stock in a transaction on Monday, March 5th. The shares were sold at an average price of $6.73, for a total transaction of $134,600.00. Following the completion of the sale, the chief operating officer now owns 908,356 shares in the company, valued at approximately $6,113,235.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 4.60% of the company’s stock.
A number of hedge funds have recently made changes to their positions in the business. Vanguard Capital Wealth Advisors purchased a new position in Arrowhead Pharmaceuticals during the 4th quarter worth $119,000. Macquarie Group Ltd. purchased a new position in Arrowhead Pharmaceuticals during the 4th quarter worth $123,000. Jane Street Group LLC purchased a new position in Arrowhead Pharmaceuticals during the 4th quarter worth $130,000. Two Sigma Investments LP purchased a new position in Arrowhead Pharmaceuticals during the 4th quarter worth $146,000. Finally, Dimensional Fund Advisors LP boosted its holdings in Arrowhead Pharmaceuticals by 252.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 44,358 shares of the biotechnology company’s stock worth $192,000 after acquiring an additional 31,765 shares during the last quarter. Institutional investors and hedge funds own 26.88% of the company’s stock.
WARNING: This piece was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://ledgergazette.com/2018/03/17/brokerages-set-arrowhead-pharmaceuticals-inc-arwr-target-price-at-4-70.html.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.